Research Publications

  1. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E.  Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.  Clin Cancer Res 2000 Mar;6(3):909-15.  PMID: 10741715
  2. Graner M, Raymond A, Akporiaye E, Katsanis E.  Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines.  Cancer Immunol Immunother 2000 Nov;49(9):476-84.  PMID: 11092614
  3. He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E.  Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.  Cancer Immunol Immunother 2001 Mar;50(1):31-40.  PMID: 11315508
  4. Feng H, Zeng Y, Whitesell L, Katsanis E.  Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity.  Blood 2001 Jun 1;97(11):3505-12. PMID: 11369644
  5. Feng H, Zeng Y, Graner MW, Katsanis E.  Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells.  Blood 2002 Dec 1;100(12):4108-15. PMID: 12393401
  6. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E.  Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity.  Blood 2003 Jan 1;101(1):245-52. PMID: 12393411
  7. Graner MW, Zeng Y, Feng H, Katsanis E.  Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003 Apr;52(4):226-34. PMID: 12669247
  8. Zeng Y, Feng H, Graner MW, Katsanis E.  Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.  Blood 2003 Jun 1;101(11):4485-91 PMID: 12576309
  9. Feng H, Zeng Y, Graner MW, Whitesell L, Katsanis E.  Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway.  J Biomed Biotechnol (Biomed Res Int) 2004 2004(1):41-51.  PMID:15123887, PMCID: PMC545657
  10. Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.  Int J Cancer 2004 Jun 10;110(2):251-9.  PMID: 15069690
  11. Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romanoski A, Thompson S, Akporiaye E, Katsanis E.  Cargo from tumor-expressed albumin inhibits T-cell activation and responses.  Cancer Res 2004 Nov 1;64(21):8085-92.  PMID: 15520220
  12. Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E.  Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.  Blood 2005 Mar 1;105(5):2016-22. PMID:15374884 PMCID: PMC1227556
  13. Zeng Y, Graner MW, Katsanis E.  Chaperone-rich cell lysates, immune activation and tumor vaccination.   Cancer Immunol Immunother 2006 Mar;55(3):329-38.  PMID: 15887013
  14. Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E.  Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.  Biol Blood Marrow Transplant 2006 Mar;12(3):275-83.  PMID: 16503496
  15. Zeng Y, Chen X, Larmonier N, Larmonier C, Li G, Sepassi M, Marron M, Andreansky S, Katsanis E.  Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination.  Int J Cancer 2006 Dec 1;119(11):2624-31.  PMID: 16989012
  16. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E.  Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.  Cancer Immunol Immunother 2007 Jan;56(1):48-59.  PMID: 16612596
  17. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, Wu C, Larmonier N, Zhang W, Zhang H, Wang H, Katsanis E.  CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease.  Clin Immunol 2007 Apr;123(1):50-9.  PMID: 17234458
  18. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E.  Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.  Clin Exp Immunol 2007 Apr;148(1):136-45.  PMID: 17349014 PMCID: PMC1868858 
  19. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E.  Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.  FASEB J 2007 Jul;21(9):2173-84.  PMID: 17327358
  20. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, Lacasse CL, Larmonier N, Penichet ML, Katsanis E.  A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.  Mol Cancer Ther 2008 Mar;7(3):721-9.  PMID:18347157,
  21. Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, Sepassi M, Andreansky S, Katsanis E.  Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.  J Leukoc Biol 2008 Apr;83(4):1049-59.  PMID: 18174364
  22. Larmonier N, Janikashvili N, LaCasse C, Larmonier C, Cantrell J, Situ E, Li G, Bonnotte B, Katsanis E.  Imatinib mesylate suppresses CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL negative tumors.  J Immunol 2008 Nov 181:6955-63.  PMID: 18981115, PMCID: PMC2579962
  23. Janikashvili N, Larmonier N, Katsanis E.  Personalized dendritic cell-based tumor immunotherapy.   Immunother 2010 Jan 2(1):57-68.  PMID: 20161666 PMCID: PMC2819192
  24. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E.  Killer dendritic cells and their potential for cancer immunotherapy.  Cancer Immunol Immunother 2010 Jan 59(1):1-11. PMID: 19618185
  25. Cantrell J, Larmonier C, Janikashvili N, Bustamante S, Fraszczak J, Herrell A, Lundeen T, LaCasse C, Situ E, Larmonier N, Katsanis E.  Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.  Immunobiology 2010 July 215(7):535–544. PMID:19880213, PMCID: PMC2881173
  26. Janikashvili N, LaCasse C, Larmonier C, Trad M, Herrell A, Bustamante S, Har-Noy M, Larmonier N, Katsanis E.  Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T cells and synergize with chaperone-rich cell lysate vaccine to treat leukemia.  Blood 2011 Feb 3;117(5):1555-64.  PMID:21123824, PMCID: PMC3056591   
  27. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. The dendritic cell-regulatory T lymphocyte cross-talk contributes to tumor-induced tolerance.  Clin Dev Immunol (J Immunol Res) 2011 2011:430394. PMID:22110524, PMCID: PMC3216392
  28. LaCasse CJ, Janikashvili N, Larmonier C, Alizadeh D, Hanke NT, Kartchner J, Situ E, Centuori S,  Bonnotte B, Katsanis E*, Larmonier N*.  T helper-1 lymphocytes induce the tumor killing function of dendritic cells by an interferon-γ-dependent mechanism.  J Immunol 2011 Dec 15;187(12):6310-7. PMID: 22075702, PMCID: PMC3297475
  29. Larmonier N, Bonnotte B, Katsanis E.  Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. Oncoimmunol 2012 Jul 1;1(4):566-568.  PMID:22754789, PMCID: PMC3382885
  30. Centuori S, Larmonier C, LaCasse CJ, Hanke NT, Kartchner J, Janikashvili N, Trad M, Alizadeh D, Bonnotte B, Larmonier N, Katsanis E.  Myeloid-derived suppressor cells from tumor bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ regulatory T cells from CD4+CD25-FoxP3- T cells. J Leukocyte Biol 2012 Nov;92(5):987-97. PMID:22891289, PMCID: PMC3476240
  31. Hanke NT, Alizadeh D, Katsanis E, Larmonier N.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.  Crit Rev Immunol 2013 33(1):1-21.  PMID:23510023, PMCID: PMC3694804
  32. Alizadeh D, Katsanis E, Larmonier N.  The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer.  Clin Dev Immunol (J Immunol Res) 2013 2013:957878. PMID:24454480, PMCID: PMC3888704
  33. Graner MW, Romanoski A, Katsanis E.  The “peptidome” of tumor-derived chaperone-rich cell lysate (CRCL) reveals potential antigens that stimulate tumor immunity.  Int J Hyperther 2013 Aug;29(5):380-9.  PMID:23725202
  34. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Har-Noy M, Lillehei KO, Katsanis E, Graner MW.  Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumor-derived chaperone-rich cell lysate (CRCL) vaccine.  Int J Hyperther 2013 Aug;29(5):390-8. PMID:23786302
  35. Alizadeh D, Katsanis E, Larmonier N.  Chemotherapeutic targeting of myeloid-derived suppressor cells Oncoimmunol 2014 Jan 1;3(1):e273381-3.  PMID:24653963, PMCID: PMC3960296
  36. Alizadeh D, Trad M, Katsanis E, Larmonier N.  Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T cell transfer in breast cancer.  Cancer Res 2014 Jan;74(1):104-18.  PMID:24197130, PMCID: PMC3896092
  37. Hanke NT, LaCasse CJ, Larmonier C, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N.  PIAS1 and STAT-3 impair the tumoricidal of IFN-γ-stimulated mouse dendritic cells generated with IL-15. Eur J Immunol 2014 Aug;44(8):2489-99. PMID:24777831, PMCID: PMC4141036
  38. Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances graft-versus-leukemia with limited graft-versus-host disease.  Bone Marrow Transplant 2014 Aug;49(8):1076-83.  PMID:24777185
  39. Graner M, Lillehei KO, Katsanis E.  Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines.  Front Oncol 2015 Jan;4:379. PMID:25610811, PMCID: PMC4285071
  40. Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E..  Post-transplant bendamustine reduces graft versus host disease while preserving graft versus leukemia in experimental haploidentical bone marrow transplantation.  Br J Haematol 2016 Jul;174(1):102-16. PMID:27030315, PMCID: PMC4917459
  41. Zeng Y, Hahn S, Stokes J, Hoffman E, Proytcheva M, Schmelz M, Chernoff J, Katsanis E.  Pak2 regulates myeloid derived suppressor cell development in mice. Blood Adv 2017 Oct 10; 1(22):1923-33. PMID:29296839, PMCID: PMC5728145
  42. Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y.  Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies.  Biol Blood Marrow Transplant 2018 Oct; 24(10):2034-2039. PMID:29908231, PMCID: PMC7556327.
  43. Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, Katsanis E. Bendamustine with total body irradiation limits murine graft versus host disease in part through effects on myeloid derived suppressor cells. Biol Blood Marrow Transplant 2019 Mar;25(3):405-416. PMID:30326280, PMCID: PMC7571287.
  44. Stokes J, Hoffman EA, Molina MS, Kummet N, Simpson RJ, Zeng Y, Katsanis E.  Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell dependent graft-versus-leukemia. Oncoimmunol 2020 Apr 30;9(1):1758011. PMID:32391190, PMCID: PMC7199810
  45. Katsanis E, Maher K, Roe D, Simpson RJ. Progressive substitution of post-transplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. eJHaem 2020 May 26, 2020;1(1), 286-292.  doi: 10.1002/jha2.20
  46. Molina MS, Stokes J, Hoffman EA, Eremija J, Zeng Y, Simpson RJ, Katsanis E. Bendamustine conditioning skews murine host dendritic cells toward pre-cDC1s and reduces graft-versus-host disease independently of Batf3.  Front Immunol 2020 July 16;11:1410.  PMID:32765499, PMCID: PMC7378358
  47. Stokes J, Molina MS, Hoffman EA, Simpson RJ, Zeng Y, Katsanis E.  Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. Cancers 2021 Apr 3;13(7):1702. PMID:33916711, PMCID: PMC8038415
  48. Molina MS, Hoffman EA, Stokes J, Kummet N, Smith KA, Baker FL, Zúñiga T, Simpson RJ, Katsanis E.  Regulatory dendritic cells induced by bendamustine, are associated with enhanced Flt3 signaling and alloreactive T-cell death. Front Immunol 2021 Jun 24;12:699128. PMID:34249005, PMCID: PMC8264365

Waiting on list